Mirtazapina Almus (Mirtazapine)

Mirtazapine, the active ingredient in Mirtazapina Almus, is a NaSSA (noradrenergic and specific serotonergic antidepressant) presented as an oral tablet for oral use. It treats major depressive disorder in adult patients. GNH USA supplies Mirtazapina Almus as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Mirtazapine is indicated for conditions within the depressive disorder spectrum.

- Major depressive disorder: reduces depressive symptoms and improves mood in adults. - Depressive disorder with melancholic features: alleviates profound sadness, loss of pleasure, and psychomotor retardation. - Major depressive disorder with insomnia: helps improve sleep quality while treating depressive symptoms.

Mirtazapine may cause a range of adverse reactions, varying in frequency and severity.

Common Side Effects: - Sedation or drowsiness - Increased appetite and weight gain - Dry mouth - Constipation - Dizziness - Orthostatic hypotension

Serious or Rare Side Effects: - Agranulocytosis or severe neutropenia - Stevens‑Johnson syndrome or toxic epidermal necrolysis - Suicidal thoughts or behavior, especially early in treatment - Seizures - Hepatic dysfunction - Severe allergic reactions (anaphylaxis)

Before initiating therapy, consider the following safety measures.

- Weight monitoring: anticipate possible weight gain and counsel patients on nutrition. - Suicidal ideation: assess for worsening depression or suicidal thoughts, particularly during the first weeks. - Hepatic impairment: use caution and consider dose adjustment in patients with liver disease. - Discontinuation: avoid abrupt cessation to reduce risk of rebound insomnia or agitation. - Elderly patients: start at low dose due to increased sensitivity to sedation and orthostatic effects. - Store at room temperature: keep in the original container, protect from moisture and direct sunlight.

Mirtazapine can interact with several drug classes; awareness helps prevent adverse outcomes.

Major Interactions (Avoid): - Monoamine oxidase inhibitors (MAOIs): risk of hypertensive crisis and serotonin syndrome. - Other serotonergic agents (e.g., SSRIs, SNRIs, tramadol): heightened risk of serotonin syndrome.

Moderate Interactions (Monitor Closely): - CNS depressants (e.g., benzodiazepines, alcohol): additive sedation and respiratory depression. - CYP2D6 or CYP3A4 inhibitors (e.g., fluoxetine, ketoconazole): may increase mirtazapine plasma levels. - CYP inducers (e.g., carbamazepine, rifampin): may reduce therapeutic effect. - Antihistamines: potential for excessive sedation. - Warfarin: monitor INR as mirtazapine may affect coagulation parameters.